Axsome Therapeutics, Inc. (NASDAQ:AXSM) Holdings Increased by Geode Capital Management LLC

Geode Capital Management LLC raised its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 2.7% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 908,459 shares of the company's stock after purchasing an additional 23,564 shares during the quarter. Geode Capital Management LLC owned 1.87% of Axsome Therapeutics worth $81,659,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the business. Bank of New York Mellon Corp grew its position in shares of Axsome Therapeutics by 7.7% during the second quarter. Bank of New York Mellon Corp now owns 165,564 shares of the company's stock worth $13,328,000 after buying an additional 11,793 shares in the last quarter. Peregrine Capital Management LLC boosted its stake in Axsome Therapeutics by 1.4% during the 2nd quarter. Peregrine Capital Management LLC now owns 87,373 shares of the company's stock valued at $7,034,000 after acquiring an additional 1,238 shares during the last quarter. Rhumbline Advisers grew its holdings in Axsome Therapeutics by 5.1% during the 2nd quarter. Rhumbline Advisers now owns 54,931 shares of the company's stock worth $4,422,000 after acquiring an additional 2,674 shares in the last quarter. Arizona State Retirement System increased its position in shares of Axsome Therapeutics by 2.1% in the 2nd quarter. Arizona State Retirement System now owns 8,630 shares of the company's stock worth $695,000 after purchasing an additional 177 shares during the last quarter. Finally, Torray Investment Partners LLC raised its stake in shares of Axsome Therapeutics by 11.5% in the 2nd quarter. Torray Investment Partners LLC now owns 11,747 shares of the company's stock valued at $946,000 after purchasing an additional 1,209 shares in the last quarter. Institutional investors and hedge funds own 81.49% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently commented on AXSM shares. Wells Fargo & Company assumed coverage on Axsome Therapeutics in a research note on Tuesday, September 3rd. They issued an "overweight" rating and a $140.00 price target for the company. Royal Bank of Canada lifted their target price on Axsome Therapeutics from $130.00 to $131.00 and gave the stock an "outperform" rating in a research report on Friday, October 4th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $121.00 price target on shares of Axsome Therapeutics in a report on Thursday, December 12th. Robert W. Baird raised their price objective on Axsome Therapeutics from $112.00 to $116.00 and gave the stock an "outperform" rating in a research note on Wednesday, November 13th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $130.00 target price on shares of Axsome Therapeutics in a research note on Tuesday, November 12th. One equities research analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $125.93.

Axsome Therapeutics Stock Performance

NASDAQ AXSM traded up $0.99 on Friday, hitting $90.73. The stock had a trading volume of 956,380 shares, compared to its average volume of 610,942. The company's 50-day moving average is $93.65 and its two-hundred day moving average is $87.98. Axsome Therapeutics, Inc. has a one year low of $64.11 and a one year high of $105.00. The stock has a market cap of $4.40 billion, a price-to-earnings ratio of -13.89 and a beta of 1.18. The company has a quick ratio of 2.37, a current ratio of 2.44 and a debt-to-equity ratio of 1.97.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.34) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.38) by $0.04. The business had revenue of $104.76 million during the quarter, compared to analyst estimates of $98.71 million. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. During the same period in the prior year, the company posted ($1.32) EPS. On average, analysts expect that Axsome Therapeutics, Inc. will post -4.6 earnings per share for the current year.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.